Can Abbott Stock Deliver on Its Second-Half Growth Promise?

Abbott Laboratories (ABT) is forecasting a significant acceleration in growth in the second half of the year, according to an analysis by Trefis. However, this optimistic outlook comes amid a slowdown in the company's primary growth driver and other operational hurdles.

Details

The report highlights that Abbott, listed on the NYSE under ticker ABT, is banking on a strong rebound in H2 2026 after a weaker-than-expected first half. Nevertheless, its main growth engine—the continuous glucose monitoring (CGM) device segment—is experiencing slowing sales due to increased competition and market saturation in some regions. The company also faces supply chain challenges and regulatory pressures.

Context

These forecasts come at a time when healthcare companies are under pressure to deliver sustainable growth. Abbott, competing with Johnson & Johnson (JNJ), Thermo Fisher (TMO), and Danaher (DHR), is seeking to diversify its revenue streams through new products in diagnostics and nutrition.

What This Means for Investors

Investors must assess whether the second-half growth expectations are realistic given the current challenges. Future performance may hinge on the company's ability to overcome execution hurdles and maintain its market share in the medical devices sector.